Vasopressin responsiveness of subclinical Cushing's syndrome due to ACTH‐independent macronodular adrenocortical hyperplasia

objective  Vasopressin (AVP) is reported to be an important factor for regulating cortisol secretion in patients with Cushing's syndrome due to ACTH‐independent macronodular adrenocortical hyperplasia (AIMAH). Recently, there have been several case reports of subclinical Cushing's syndrome due to AIMAH, in which the pathophysiological role of AVP has been unknown. The aim was to conduct an extensive investigation of AVP in the autonomous secretion of cortisol in subclinical Cushing's syndrome due to AIMAH.

[1]  P. Hamet,et al.  Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  P. Hamet,et al.  Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. , 2001, Endocrine reviews.

[3]  P. Hamet,et al.  Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. , 1999, The New England journal of medicine.

[4]  L. Gaboury,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Asynchronous Development of Bilateral Nodular Adrenal Hyperplasia in Gastric Inhibitory Polypeptide- Dependent Cushing’s Syndrome* , 1998 .

[5]  T. Usdin,et al.  Food-dependent Cushing's syndrome: characterization and functional role of gastric inhibitory polypeptide receptor in the adrenals of three patients. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  Shibata,et al.  In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH‐independent bilateral macronodular adrenocortical hyperplasia , 1998, Clinical endocrinology.

[7]  P. Chaffanjon,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Cushing’s Syndrome due to a Gastric Inhibitory Polypeptide-Dependent Adrenal Adenoma: Insights into Hormonal Control of Adrenocortical Tumorigenes , 2022 .

[8]  G. Arnaldi,et al.  Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[9]  G. Rousseau,et al.  Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. , 1997, The New England journal of medicine.

[10]  M. Kameyama,et al.  Preclinical Cushing's syndrome due to adrenocorticotropin-independent bilateral adrenocortical macronodular hyperplasia with concurrent excess of gluco- and mineralocorticoids. , 1997, Internal medicine.

[11]  E. Schiffrin,et al.  Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  H. Bonjer,et al.  Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. , 1996, The Journal of clinical endocrinology and metabolism.

[13]  K. Takahashi,et al.  Three cases of clinical or preclinical Cushing's syndrome due to adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia: pituitary-adrenocortical function and immunohistochemistry. , 1995, Internal medicine.

[14]  H. Vaudry,et al.  Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.

[15]  T. Suda,et al.  Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. , 1995, The Journal of clinical endocrinology and metabolism.

[16]  O. Manzoni,et al.  Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. , 1995, Endocrinology.

[17]  N. S. Ross.  Epidemiology of Cushing's syndrome and subclinical disease. , 1994, Endocrinology and metabolism clinics of North America.

[18]  H. Vaudry,et al.  Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. , 1993, The Journal of clinical endocrinology and metabolism.

[19]  P. Leymarie,et al.  Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. , 1992, The New England journal of medicine.

[20]  P. Poitras,et al.  Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. , 1992, The New England journal of medicine.

[21]  T. Saruta,et al.  Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing's syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of the literature. , 1991, American journal of clinical pathology.

[22]  D. Ross,et al.  Incidentally discovered adrenal masses. , 1989, American journal of surgery.

[23]  D. Page,et al.  Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. , 1989, The Journal of clinical endocrinology and metabolism.

[24]  P. Hamet,et al.  Cushing syndrome with food-dependent periodic hormonogenesis. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[25]  A. Tabarin,et al.  Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  D. Aron,et al.  Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. , 1993, The Journal of clinical endocrinology and metabolism.